Dianthus Therapeutics 320% Year: What Investors Should Know as Stakes Shift
Dianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
Regular budget reviews involve quick weekly checks and a deeper monthly audit to refine categories and improve long-term financial health.
14,490 articlesDianthus Therapeutics has surged 320% over the past year, even as a large investor reduced its stake. This article di...
A large fund sold about $17 million in ZoomInfo shares while the company posted slim revenue growth. This article bre...
Despite stronger wages, many americans feel broke as inflation lingers and debt burdens grow. This report explores wh...
Retirees should anchor planning on cash flow rather than asset size. Here is how the math stacks up in today's market...
President Trump delayed signing an AI executive order after a late lobbying blitz by major tech figures. The move hig...
A broad study shows younger adults delaying key life events, pressuring insurers to rethink offerings as 'living bene...
Rosewood Hotels announces a 16-week globally paid parental leave policy for all employees, including adopters, signal...
A Texas primary shock sends markets into a risk-off mode as sen. john cornyn becomes a flashpoint for party fault lin...
Salesforce unveiled a record $25 billion accelerated share repurchase funded by debt as it posted quarterly results. ...
Dollar Tree beat expectations and raised its full-year outlook, sending its shares higher as fewer shoppers visit, bu...
Tesla faces a pivotal 2H 2026. This guide breaks down the catalysts, the risks, and practical steps investors can tak...
NVDY's option-income approach pays steady income but caps upside, leading nvdy investors to miss half of NVIDIA's exp...